Suchergebnisse - "Capobianco, Marco"

PubPharm (169)

81

Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register

enthalten in: Journal of neurology | 2019

von Paolicelli, D. | Lucisano, G. | Manni, A. | +30

82

Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study

enthalten in: Journal of neurology | 2019

von Frau, J. | Saccà, F. | Signori, A. | +17

83

Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study

enthalten in: Journal of neurology | 2019

von Frau, J. | Saccà, F. | Signori, A. | +17

84

Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study

enthalten in: Journal of neurology | 2019

von Frau, J. | Saccà, F. | Signori, A. | +17

85

Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents : A multicentre, Italian, retrospective, observational study

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2019

von Baroncini, D. | Zaffaroni, M. | Moiola, L. | +23

ErratumIn: Mult Scler. 2019 Oct;25(11):NP33. - PMID 31287376

86

Early diagnosis of progressive multifocal leucoencephalopathy : longitudinal lesion evolution

enthalten in: Journal of neurology, neurosurgery, and psychiatry | 2019

von Scarpazza, C. | Signori, A. | Prosperini, L. | +56

87

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis : a 36-month real-world study

enthalten in: Journal of neurology | 2018

von Prosperini, L. | Annovazzi, P. | Boffa, L. | +65

88

Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders

enthalten in: Neurology(R) neuroimmunology & neuroinflammation | 2018

von Marcinnò, A. | Marnetto, F. | Valentino, P. | +7

89

Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?

enthalten in: Journal of the neurological sciences | 2017

von Scarpazza, C. | Prosperini, L. | Mancinelli, C. | +8

ErratumIn: J Neurol Sci. 2017 Sep 15;380:19. - PMID 28870565

90

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab : an Observational Study

enthalten in: Neurology and therapy | 2017

von Malucchi, S. | Capobianco, M. | Lo Re, M. | +5